VRAY - ViewRay, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.03
+0.23 (+3.38%)
At close: 4:00PM EST

7.17 +0.14 (1.99%)
After hours: 6:24PM EST

Stock chart is not supported by your current browser
Previous Close6.80
Open6.81
Bid7.17 x 4000
Ask7.25 x 900
Day's Range6.81 - 7.11
52 Week Range4.86 - 13.21
Volume781,301
Avg. Volume1,340,395
Market Cap672.983M
Beta (3Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-1.18
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.08
Trade prices are not sourced from all markets
  • ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 Results
    PR Newswire9 days ago

    ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 Results

    CLEVELAND, Jan. 7, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The preliminary results have not been audited and are subject to change. This resulted in total fourth quarter 2018 revenue of approximately $21 million, compared to fourth quarter 2017 revenue of $19.9 million, primarily from four revenue units.

  • ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic Cancer
    PR Newswire12 days ago

    ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic Cancer

    CLEVELAND, Jan. 4, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today the enrollment of the first patient in the Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial, a multi-center, prospective clinical trial for locally advanced or borderline pancreatic cancer. The trial will explore the clinical benefits of precise, high dose radiation therapy enabled by MR-guidance combined with daily on-table adaptation in the treatment of pancreatic cancer. Retrospective analysis of precise, high-dose MR-guided radiation therapy delivered using adaptive dose planning has shown promising results with locally advanced pancreatic cancer, suggesting the potential for improving overall survival relative to patients receiving lower radiation doses, without increasing the rate of serious gastrointestinal toxicity. The compelling nature of the retrospective data prompted the SMART trial, aimed at investigating in a controlled, prospective manner, the robustness of this outcome and tracking quality of life over a 5-year trial period.

  • Have Insiders Been Buying ViewRay, Inc. (NASDAQ:VRAY) Shares?
    Simply Wall St.27 days ago

    Have Insiders Been Buying ViewRay, Inc. (NASDAQ:VRAY) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • Is ViewRay, Inc. (VRAY) A Good Stock To Buy?
    Insider Monkeylast month

    Is ViewRay, Inc. (VRAY) A Good Stock To Buy?

    “Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]

  • ViewRay® to Present at the 37th Annual J.P. Morgan Healthcare Conference
    PR Newswirelast month

    ViewRay® to Present at the 37th Annual J.P. Morgan Healthcare Conference

    CLEVELAND , Dec. 10, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California . ...

  • Why ViewRay Stock Lost 22% in November
    Motley Foollast month

    Why ViewRay Stock Lost 22% in November

    Investors weren't happy with the radiation therapy specialist's latest earnings results.

  • GlobeNewswirelast month

    Report: Exploring Fundamental Drivers Behind Wayfair, TEGNA, Genpact, ViewRay, United States Steel, and Windstream — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Rob Fuchs joins ViewRay as Chief Human Resources Officer
    PR Newswire2 months ago

    Rob Fuchs joins ViewRay as Chief Human Resources Officer

    CLEVELAND , Nov. 21, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the world's first and only clinical MRI-guided radiation therapy system, announced today the appointment of Robert M. Fuchs ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of VRAY earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 ViewRay Inc Earnings Call

  • ViewRay® to Present at 30th Annual Piper Jaffray Healthcare Conference
    PR Newswire2 months ago

    ViewRay® to Present at 30th Annual Piper Jaffray Healthcare Conference

    CLEVELAND , Nov. 14, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that company management is scheduled to participate in a fireside chat at the 30 th Annual Piper Jaffray Healthcare ...

  • GuruFocus.com2 months ago

    Viewray Inc (VRAY) President & CEO Scott William Drake Bought $388,200 of Shares

    President & CEO of Viewray Inc (NASDAQ:VRAY) Scott William Drake bought 60,000 shares of VRAY on 11/13/2018 at an average price of $6.47 a share.

  • Why ViewRay Inc. Is Sinking Today
    Motley Fool2 months ago

    Why ViewRay Inc. Is Sinking Today

    Shares plunge after the company reports third-quarter results that missed the mark and lowers guidance. Is something wrong with the business?

  • Associated Press2 months ago

    ViewRay: 3Q Earnings Snapshot

    The Oakwood Village, Ohio-based company said it had a loss of 39 cents per share. Losses, adjusted for non-recurring costs and severance costs, came to 25 cents per share. The results missed Wall Street ...

  • ViewRay Reports Third Quarter 2018 Results
    PR Newswire2 months ago

    ViewRay Reports Third Quarter 2018 Results

    CLEVELAND , Nov. 8, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) ("the Company") today announced financial results for the third quarter ended September 30, 2018 . Third Quarter 2018 Highlights: ...

  • ViewRay signs agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy systems to the UK
    PR Newswire3 months ago

    ViewRay signs agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy systems to the UK

    CLEVELAND, Oct. 29, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY) today announced a collaboration with GenesisCare, the largest provider of cancer services in the UK, Spain and Australia, to introduce the first MRIdian MRI-guided radiotherapy system in the UK to benefit cancer patients.

  • GlobeNewswire3 months ago

    Report: Developing Opportunities within Vitamin Shoppe, Intercept Pharmaceuticals, Viasat, Team, Valvoline, and ViewRay — Future Expectations, Projections Moving into 2018

    NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Real-Time Adaptive Radiotherapy Capabilities of ViewRay's MRIdian Highlighted at Investor & Analyst Meeting at ASTRO 2018
    PR Newswire3 months ago

    Real-Time Adaptive Radiotherapy Capabilities of ViewRay's MRIdian Highlighted at Investor & Analyst Meeting at ASTRO 2018

    The meeting featured presentations highlighting clinical experiences with the MRIdian System from leading radiation oncologists at the Moffitt Cancer Center and David Geffen School of Medicine at UCLA. A presentation by Louis B. Harrison, M.D., FASTRO, Chair and Senior Member, Department of Radiation Oncology at Moffitt Cancer Center, highlighted the opportunity for MRI-guided radiotherapy in the treatment of cancer and its potential contribution to personalizing radiation therapy including emerging areas of interest such as optimization of treatment through an adaptive therapy loop and diffusion weighted imaging to predict tumor response.

  • ViewRay Announces Conference Call and Webcast of Third Quarter 2018 Financial Results to be Held After Market on November 8, 2018
    PR Newswire3 months ago

    ViewRay Announces Conference Call and Webcast of Third Quarter 2018 Financial Results to be Held After Market on November 8, 2018

    CLEVELAND , Oct. 18, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2018 financial results, which will take place after the market ...

  • ASTRO 2018 Presentations to Feature Unique Capabilities and Clinical Outcomes of ViewRay's MRIdian Next Generation Cancer Care
    PR Newswire3 months ago

    ASTRO 2018 Presentations to Feature Unique Capabilities and Clinical Outcomes of ViewRay's MRIdian Next Generation Cancer Care

    Presentations to Highlight Clinical Value of World's Only FDA-Cleared MRI-guided Radiotherapy System CLEVELAND , Oct. 16, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's ...

  • ViewRay® to Host Investor & Analyst Meeting at 2018 ASTRO Annual Meeting in San Antonio
    PR Newswire3 months ago

    ViewRay® to Host Investor & Analyst Meeting at 2018 ASTRO Annual Meeting in San Antonio

    Leading Oncologists to Highlight MRIdian MRI-Guided Adaptive Radiotherapy, Discuss Emergence as a New Potential Standard of Cancer Care CLEVELAND , Oct. 9, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) ...

  • Simply Wall St.3 months ago

    What does ViewRay Inc’s (NASDAQ:VRAY) Balance Sheet Tell Us About Its Future?

    Investors are always looking for growth in small-cap stocks like ViewRay Inc (NASDAQ:VRAY), with a market cap of US$890m. However, an important fact which most ignore is: how financially healthy Read More...

  • ViewRay Appoints Industry Veteran James Alecxih as Chief Commercial Officer
    PR Newswire3 months ago

    ViewRay Appoints Industry Veteran James Alecxih as Chief Commercial Officer

    CLEVELAND, Oct. 2, 2018  /PRNewswire/ -- ViewRay, Inc. (VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the appointment of James "Jim" Alecxih as Chief Commercial Officer, effective September 17th, 2018. Mr. Alecxih joins the ViewRay leadership team with extensive experience in commercializing new and innovative devices globally and will be responsible for driving the Company's commercial expansion. Prior to joining ViewRay, Mr. Alecxih served as Vice President of Worldwide Sales at Nevro, where he led the high-growth neuromodulation device company's commercial efforts across multiple geographies.  Mr. Alecxih also spent 14 years at Intuitive Surgical, where he served most recently as Senior Vice President of Sales for North America, South America, Australia and New Zealand.

  • MRI-Guided Radiation Therapy Aims to Prolong Survival and Reduce Complications for the Most Challenging Cancers
    PR Newswire4 months ago

    MRI-Guided Radiation Therapy Aims to Prolong Survival and Reduce Complications for the Most Challenging Cancers

    CLEVELAND, Oct. 1, 2018 /PRNewswire/ -- Leading oncology experts from around the world met to discuss the integration of magnetic resonance imaging (MRI) with radiation therapy and its potential to extend life expectancy and reduce common side effects in many cancer patients. ViewRay, Inc. (VRAY), maker of MRIdian®, the world's first and only FDA-cleared, MRI-guided radiation therapy system, and Miami Cancer Institute, co-hosted experts from research hospitals at the cutting-edge of cancer treatment at the September 28 symposium and panel discussion.

  • Exploring ViewRay’s Operational Performance
    Market Realist4 months ago

    Exploring ViewRay’s Operational Performance

    ViewRay (VRAY) incurred general and administrative expenses of $10.5 million in the second quarter compared to $7.46 million in the second quarter of 2017. Its selling and marketing expenses increased from $1.87 million in the second quarter of 2017 to $3.39 million in the second quarter of 2018 due to an increase in its head count to support its growing sales efforts.

  • What ViewRay’s Valuation Trend Indicates
    Market Realist4 months ago

    What ViewRay’s Valuation Trend Indicates

    In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating. The mean rating for ViewRay stock is a 2, and its target price is $12.71, implying an upside potential of 30.8% over its closing price of $9.72 on September 27. In comparison, for peers Intuitive Surgical (ISRG), Medtronic (MDT), and Zimmer Biomet Holdings (ZBH), analysts have mean ratings of 2.06, 2.24, and 2.25, respectively, and target prices of $565.8, $102.45, and $136.39, respectively.